|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
WO2005037235A2
(en)
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
EP1894715B8
(de)
|
2006-08-31 |
2010-11-10 |
Treofan Germany GmbH & Co.KG |
Biaxial orientierte Elektroisolierfolie
|
|
US8236074B1
(en)
|
2006-10-10 |
2012-08-07 |
Us Synthetic Corporation |
Superabrasive elements, methods of manufacturing, and drill bits including same
|
|
WO2008052796A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
JP2010528285A
(ja)
|
2007-05-23 |
2010-08-19 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
|
|
JP5628145B2
(ja)
|
2008-03-19 |
2014-11-19 |
ケムブリッジ・コーポレーション |
新規チロシンキナーゼ阻害剤
|
|
EP2276506A4
(en)
|
2008-04-30 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
EP2374481B1
(en)
|
2008-07-21 |
2015-11-04 |
Polytherics Limited |
Novel reagents and method for conjugating biological molecules
|
|
AR073770A1
(es)
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
TWI507205B
(zh)
|
2009-03-25 |
2015-11-11 |
Genentech Inc |
抗ｆｇｆｒ３抗體及使用方法
|
|
AU2010242914B2
(en)
|
2009-04-29 |
2014-11-13 |
Trellis Bioscience, Llc |
Improved antibodies immunoreactive with heregulin-coupled HER3
|
|
EP2450055B1
(en)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
JP5954789B2
(ja)
|
2009-08-10 |
2016-07-20 |
ユーシーエル ビジネス パブリック リミテッド カンパニー |
機能的分子の可逆的共有結合
|
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
MA33892B1
(fr)
|
2009-12-22 |
2013-01-02 |
Roche Glycart Ag |
Anticorps anti-her3, et leurs utilisations
|
|
CA2792327C
(en)
|
2010-03-11 |
2019-09-24 |
Merrimack Pharmaceuticals, Inc. |
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
CN102884085B
(zh)
|
2010-04-09 |
2016-08-03 |
Aveo制药公司 |
抗erbb3抗体
|
|
DK2528625T3
(da)
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
WO2012015674A1
(en)
|
2010-07-26 |
2012-02-02 |
Eli Lilly And Company |
THERAPEUTIC USES OF AN FGFR1c ANTIBODY
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2630160B1
(en)
|
2010-10-18 |
2016-11-09 |
MediaPharma S.r.l. |
Erbb3 binding antibody
|
|
JP6033783B2
(ja)
|
2010-11-01 |
2016-11-30 |
シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ |
Ｐａｎ−ｈｅｒ抗体組成物
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
ITRM20100577A1
(it)
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
CN105884900A
(zh)
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
|
SI2710035T1
(sl)
|
2011-05-16 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Agonisti FGFR1 in tehnike njihove uporabe
|
|
KR102101806B1
(ko)
|
2011-05-19 |
2020-04-20 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-인간-her3 항체 및 이의 용도
|
|
KR20140037105A
(ko)
|
2011-05-27 |
2014-03-26 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
AU2012274461A1
(en)
|
2011-06-20 |
2014-01-16 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbB3 antibody
|
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
|
HK1200468A1
(en)
|
2011-09-30 |
2015-08-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
US9828635B2
(en)
|
2011-10-06 |
2017-11-28 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
|
WO2013055993A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
CA2850096C
(en)
|
2011-10-14 |
2018-07-03 |
Spirogen Sarl |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
ES2945932T3
(es)
|
2011-10-14 |
2023-07-10 |
Seagen Inc |
Pirrolobenzodiazepinas y conjugados dirigidos
|
|
CA2850103C
(en)
|
2011-10-14 |
2019-09-10 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
CN104244718A
(zh)
|
2011-12-05 |
2014-12-24 |
伊格尼卡生物治疗公司 |
抗体-药物缀合物以及相关化合物、组合物和方法
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
EP2837685B1
(en)
|
2012-04-09 |
2020-09-09 |
Daiichi Sankyo Company, Limited |
Anti-fgfr2 antibody
|
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
FI2911699T4
(fi)
|
2012-10-23 |
2025-12-09 |
Synaffix Bv |
Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
|
|
EP2912066A4
(en)
|
2012-10-25 |
2016-10-12 |
Sorrento Therapeutics Inc |
ANTIGENBINDING PROTEINS FOR BINDING ERBB3
|
|
WO2014105849A1
(en)
|
2012-12-28 |
2014-07-03 |
Xoma (Us) Llc |
Antibodies specific for fgfr4 and methods of use
|
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
KR20150123250A
(ko)
*
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
JP6419796B2
(ja)
|
2013-10-04 |
2018-11-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ３に特異的に結合する抗体
|
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
KR102127408B1
(ko)
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
CA2975829A1
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
|
MX2016014862A
(es)
|
2014-05-14 |
2017-02-27 |
Hoffmann La Roche |
Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
|
|
US20170304313A1
(en)
*
|
2014-10-06 |
2017-10-26 |
Novartis Ag |
Therapeutic Combination For The Treatment Of Cancer
|